Drug · C-X-C chemokine receptor type 4 partial agonist
1 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
Acute Lymphoblastic Leukemia · Acute Myelocytic Leukemia · Chronic Myelocytic Leukemia · Juvenile Myelomonocytic Leukemia · Myelodysplastic Syndrome · Hodgkin or Non-Hodgkin Lymphoma · Sarcoma, Myeloid
Enrolment: 34 · Results not recorded
Lymphoma (Non-Hodgkin's Lymphoma) · Hodgkin's Disease or Multiple Myeloma · Front Line Mobilization · Transplantation
Enrolment: 118 · Results not recorded
Acute Myeloid Leukemia · Acute Lymphoid Leukemia
Enrolment: 20 · Results not recorded
Non-Hodgkin's Lymphoma · Plasma Cell Myeloma
Enrolment: 77 · Results not recorded
Sickle Cell Disease · Hemoglobinopathies · Graft Failure
Enrolment: 62 · Results not recorded
Lymphoma
Enrolment: 32 · Results not recorded
Blood And Marrow Transplantation
Enrolment: 22 · Results not recorded
Multiple Myeloma
Enrolment: 25 · Results not recorded
Acute Myelogenous Leukemia
Enrolment: 22 · Results not recorded
Fanconi Anemia
Enrolment: 1 · Results not recorded
Diabetes Mellitus, Type 1
Enrolment: 22 · Results not recorded
Myelodysplastic Syndromes
Enrolment: 28 · Results not recorded
Myeloma
Enrolment: 30 · Results not recorded
Chronic Lymphocytic Leukemia · Lymphoma · Multiple Myeloma
Enrolment: 7 · Results not recorded
Chronic Lymphocytic Leukemia (CLL) · Small Lymphocytic Lymphoma (SLL)
Enrolment: 24 · Results not recorded
Cancer
Enrolment: 2 · Results not recorded
COPD · Cystic Fibrosis · Pulmonary Fibrosis
Enrolment: 15 · Results not recorded
Osteosarcoma · Bone Metastases
Enrolment: 0 · Results not recorded
Multiple Myeloma
Enrolment: 300 · Results not recorded
3 studies reported at therapy level; 3 evidence entries itemised.
Model: Radiation-induced skin injury produced by irradiation of the right hind leg; a 30 Gy exposure was used for the SDF-1 time-course measurements
Plerixafor improved both acute and late skin radiation responses, with the effect strongly dependent on timing of administration. Maximum benefit occurred when dosing started 1 week after irradiation, while earlier or later administration reduced efficacy. Cytokine levels and histologically assesse…
Extraction: extract · Supplied extraction confidence: 0.75. Machine-extracted fields require source verification.
Model: Localised skin irradiation, with mice receiving a 35 Gy dose, producing acute skin injury and subsequent fibrosis
Subcutaneous AMD3100 attenuated radiation-induced skin injury and fibrosis in rats, and keratinocyte-specific CXCR4 deletion reduced skin damage in mice, consistent with SDF-1alpha/CXCR4 driving profibrotic TGF-beta/Smad signalling.
Extraction: extract · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.
Model: Unilateral warm lung ischaemia-reperfusion under isoflurane anaesthesia and mechanical ventilation: right lateral thoracotomy with suture ligation of the right lung hilum occluding pulmonary artery, vein and right main stem bronchus for 30 minutes (series 1) or 60 minutes (series 2), followed by 300 minutes of reperfusion
CXCR4 blockade with AMD3100 worsened outcome, reducing PaO2/FiO2 ratios, converting mild into moderate ARDS, increasing histological lung injury and lowering lung IL-10, whereas the CXCR4 agonist ubiquitin dose-dependently increased PaO2/FiO2 ratios, converted moderate to severe into mild to modera…
Extraction: extract · Supplied extraction confidence: 0.95. Machine-extracted fields require source verification.
